



## Disclosures

### Personal Commercial (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen, AstraZeneca, Bayer, Biosensors, CSL Behring, Idorsia, Janssen,	Research/Research Grants	Significant ( $\geq$ \$5,000)	<i>Invasive CV Angio and Interventions</i>
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Chiesi, Janssen, Novartis, Novo Nordisk, PhaseBio, PLx Pharma, Pfizer, Sanofi, Vectura	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Invasive CV Angio and Interventions</i>
Biosensors, Daiichi-Sankyo, Eli Lilly, Haemonetics, Merck, The Medicines Company	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Invasive CV Angio and Interventions</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/1/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 10/1/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 10/1/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.